Dr. Leal addresses diagnostic challenges with newer therapies, particularly tarlatamab's potential neurologic side effects ...

Dr. Leal introduces amifampridine, an FDA-approved oral potassium channel blocker that increases acetylcholine release at ...

RAINIER is a multicenter, open-label, multi-cohort phase 1b/2 dose-optimization study enrolling adults aged 18 years or older ...

Clinical care remains anchored in disease-specific expertise, but is augmented by wraparound services tailored to life stage.

Andrzej Jakubowiak, MD, PhD, director of the multiple myeloma program at the University of Chicago, discusses the definitive results of the phase 3 ATLAS trial (NCT02659293), recently published in The ...

Dr. Ticiana Leal from Emory University's Winship Cancer Institute and Dr. Wade Iams from Tennessee Oncology introduce their ...

Dr. Leal discusses the updated NCCN guidelines recommending VGCC antibody testing for patients with suspected neurologic ...

Breakthrough therapy designation targets an unmet-need ACC population, positioning B7-H4 as a therapeutically actionable antigen in solid histology or high-grade transformed disease. Dose-escalation ...

Ultimately, Rathmell emphasizes that the BRIDGE Program represents a shift toward more holistic oncology care—one that aligns ...

First-line treatment selection in HER2-mutant NSCLC balances route of administration, efficacy data by mutation subtype, and ...

Switching to camizestrant 75 mg while continuing CDK4/6i significantly prolonged PFS to 16.0 vs 9.2 months (HR 0.44; P<.00001 ...

Antibody-drug conjugates (ADCs) have emerged as the primary solution for patients who have progressed on EGFR inhibitors and ...